Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND: CYP-001 for Respiratory Failure
NCT04537351Phase 1Completed
- Sponsor
- Cynata Therapeutics
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing CYP-001 with Standard of care (2 arms). Primary endpoint: Trend in trajectory of PaO2/FiO2 ratio at 7 days. Started Aug 2020; status: completed.
02
Drugs
Cymerus MSCs
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04537351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537351.